Bayer snagged commercial rights to BridgeBio’s lead asset, acoramidis, in Europe for $310 million. BridgeBio stock is nearing a breakout.

The post BridgeBio, A Top 3% Biotech, Just Snagged A $310 Million Deal; Will Shares Break Out? appeared first on Investor’s Business Daily.